Deprecated: Creation of dynamic property WhitelabelOptions::$_title is deprecated in /home/grassnews/public_html/wp-content/themes/zox-news/admin/admin-page.php on line 79
Schwazze Sets Third Quarter 2023 Conference Call for November 14, 2023 at 5:00 p.m. ET – GrassNews
Connect with us

SCHWAZZE

Schwazze Sets Third Quarter 2023 Conference Call for November 14, 2023 at 5:00 p.m. ET

Published

on

schwazze-sets-third-quarter-2023-conference-call-for-november-14,-2023-at-5:00-pm.-et

DENVER, Oct. 30, 2023 /PRNewswire/ — Medicine Man Technologies, Inc., operating as Schwazze, (OTCQX: SHWZ) (NEO: SHWZ) (“Schwazze” or the “Company”), will host a conference call on Tuesday, November 14, 2023 at 5:00 p.m. Eastern time to discuss its financial and operational results for the third quarter ended September 30, 2023. The Company’s results will be reported in a press release prior to the call.

The Schwazze management team will host the conference call, followed by a question-and-answer period. Interested parties may submit questions to the Company prior to the call by emailing ir@schwazze.com.

Date: Tuesday, November 14, 2023
Time: 5:00 p.m. Eastern time
Toll-free dial-in: (888) 664-6383
International dial-in: (416) 764-8650
Conference ID: 64450430
Webcast: SHWZ Q3 2023 Earnings Call

The conference call will also be broadcast live and available for replay on the investor relations section of the Company’s website at https://ir.schwazze.com.

Toll-free replay number: (888) 390-0541
International replay number: (416) 764-8677
Replay ID: 450430

Advertisement
Stake.com

If you have any difficulty registering or connecting with the conference call, please contact Elevate IR at (720) 330-2829.

About Schwazze

Schwazze (OTCQX: SHWZ) (NEO: SHWZ) is building a premier vertically integrated regional cannabis company with assets in Colorado and New Mexico and will continue to take its operating system to other states where it can develop a differentiated regional leadership position. Schwazze is the parent company of a portfolio of leading cannabis businesses and brands spanning seed to sale.

Schwazze is anchored by a high-performance culture that combines customer-centric thinking and data science to test, measure, and drive decisions and outcomes. The Company’s leadership team has deep expertise in retailing, wholesaling, and building consumer brands at Fortune 500 companies as well as in the cannabis sector.

Medicine Man Technologies, Inc. was Schwazze’s former operating trade name. The corporate entity continues to be named Medicine Man Technologies, Inc. Schwazze derives its name from the pruning technique of a cannabis plant to enhance plant structure and promote healthy growth. To learn more about Schwazze, visit www.schwazze.com.

Investor Relations Contact: Sean Mansouri, CFA or Aaron D’Souza, Elevate IR, (720) 330-2829, ir@schwazze.com

Advertisement
Stake.com

View original content:https://www.prnewswire.co.uk/news-releases/schwazze-sets-third-quarter-2023-conference-call-for-november-14-2023-at-500-pm-et-301970754.html

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

SCHWAZZE

Schwazze Announces First Quarter 2024 Financial Results

Published

on

schwazze-announces-first-quarter-2024-financial-results

Schwazze Management to Host Conference Call Today at 5:00 p.m. Eastern Time

DENVER, May 15, 2024 /PRNewswire/ — Medicine Man Technologies, Inc., operating as Schwazze, (OTCQX: SHWZ) (Cboe CA: SHWZ) (“Schwazze” or the “Company”), today announced financial and operational results for the first quarter ended March 31, 2024.

“We delivered another period of revenue growth in Q1 as we further refined our retail strategy while contending with the prolonged competitive challenges in Colorado and New Mexico,” said Forrest Hoffmaster, Interim CEO of Schwazze. “Throughout the quarter, we continued to sharpen our pricing and promotional efforts while enhancing the in-store experience, widening assortment, improving in-stock position, and advancing our loyalty program to attract and retain new customers. We also strengthened our wholesale business with quarter-over-quarter growth, while surpassing 30% total door penetration across both states.”

“The Colorado market remains highly competitive with more than 680 active recreational licenses, underscoring the importance of delivering an exceptional customer experience and fully integrated retail support program. Although retail pricing has recently stabilized, Colorado sales in Q1 were down 10% year-over-year due to lower volumes. Nonetheless, we significantly outpaced the market as our sales were up 9%, demonstrating the effectiveness of our operating playbook to compete in challenging environments. We expect to continue driving improvements in customer acquisition, retention, and loyalty as we further increase market share in the state.”

“In New Mexico, the proliferation of new licenses continued to outpace state cannabis sales as store count in Q1 increased 31% year-over-year while the market grew only 13%. In addition to pricing and promotional efforts, we’ve focused on driving traffic into our stores by expanding assortment with high quality flower and delivering an elevated customer experience. The New Mexico regulatory body has also increased its license enforcement efforts in recent months, contributing to more than 70 store closures and a 33% sequential decrease in net new store openings in the first quarter. We will continue to support the New Mexico Cannabis Control Division as it develops its regulatory framework.”

Advertisement
Stake.com

“Over the past four years we have rapidly scaled our footprint through 13 acquisitions, building a leading retail presence in both Colorado and New Mexico. We are beginning to see positive momentum from our pricing and promotional strategy and will remain focused on driving operating efficiencies while further optimizing our assets as we consolidate cultivation facilities and eliminate underperforming stores that do not meet our high-margin thresholds. We believe these initiatives, coupled with our operating playbook and strict cost controls, will enable us to return to stronger levels of profitability moving forward.”

First Quarter 2024 Financial Summary

$ in Thousands USD

Q1 2024

Q4 2023

Advertisement
Stake.com

Q1 2023

Total Revenue

$41,601

$43,325

$40,001

Advertisement
Stake.com

Gross Profit

$17,934

$7,034[1]

$21,849

Operating Expenses

Advertisement
Stake.com

$20,643

$23,276

$16,199

Income (Loss) from Operations

$(2,709)

Advertisement
Stake.com

$(16,242)

$5,650

Adjusted EBITDA[2]

$7,341

$10,953

Advertisement
Stake.com

$14,525

Operating Cash Flow

$(3,700)

$3,452

$(880)

Advertisement
Stake.com

Recent Highlights

  • Announced the grand opening of a medical and recreational dispensary in March under the Everest Apothecary banner in Las Cruces, New Mexico, increasing the Company’s retail footprint to 34 stores across the state.
  • Increased wholesale penetration in the first quarter to more than 30% of total doors in Colorado and New Mexico.
  • Lowell Herb Co. pre-roll sales increased more than 3x quarter-over-quarter in Colorado, where it continues to be the #1 pre-roll in the state.
  • Wana gummy sales up more than 2x quarter-over-quarter in New Mexico.

First Quarter 2024 Financial Results

Total revenue in the first quarter of 2024 increased 4% to $41.6 million compared to $40.0 million for the same quarter last year. The increase was primarily due to growth from new stores compared to the prior year period, partially offset by continued pricing pressure and the proliferation of new licenses in New Mexico.

Gross profit for the first quarter of 2024 was $17.9 million or 43.1% of total revenue, compared to $21.8 million or 54.6% of total revenue for the same quarter last year. The decrease in gross margin was primarily driven by the aforementioned pricing pressure in New Mexico, as well as higher medical sales mix in Colorado.

____________________________

1 Q4 2023 Gross Profit includes one-time, non-cash inventory adjustments of approximately $13.1 million comprised of $3.1 million of product consolidation, obsolescence, and shrinkage expenses, $4.3 million of net realizable value adjustments, and $5.8 million of fair value adjustments on acquired inventory in New Mexico in 2023. 
2  Adjusted EBITDA is a non-GAAP measure as defined by the SEC, and represents earnings before interest, taxes, depreciation, and amortization, adjusted for other income, non-cash share-based compensation, one-time transaction related expenses, or other non-operating costs. The Company uses Adjusted EBITDA as it believes it better explains the results of its core business. See “ADJUSTED EBITDA RECONCILIATION (NON-GAAP)” section herein for an explanation and reconciliations of non-GAAP measure used throughout this release.

Advertisement
Stake.com

Operating expenses for the first quarter of 2024 were $20.6 million compared to $16.2 million for the same quarter last year. The year-ago period benefitted from a payroll tax credit of $3.9M. The remaining increase was primarily driven by personnel expenses and four-wall SG&A costs associated with 21 additional stores in Colorado and New Mexico that are still ramping.

Loss from operations for the first quarter of 2024 was $2.7 million compared to income from operations of $5.6 million in the same quarter last year. Net loss was $16.1 million for the first quarter of 2024 compared to net income of $1.7 million for the same quarter last year.

Adjusted EBITDA for the first quarter of 2024 was $7.3 million compared to $14.5 million for the same quarter last year. The decrease in Adjusted EBITDA was primarily driven by lower gross margin and higher operating expenses associated with the 21 additional stores that are still ramping.

As of March 31, 2024, cash and cash equivalents were $13.2 million compared to $19.2 million on December 31, 2023. Total debt as of March 31, 2024, was $159.7 million compared to $156.8 million on December 31, 2023.

Conference Call

Advertisement
Stake.com

The Company will conduct a conference call today, May 15, 2024, at 5:00 p.m. Eastern time to discuss its results for the first quarter ended March 31, 2024.

Schwazze management will host the conference call, followed by a question-and-answer period. Interested parties may submit questions to the Company prior to the call by emailing ir@schwazze.com.

Date: Wednesday, May 15, 2024
Time: 5:00 p.m. Eastern time
Toll-free dial-in: (888) 664-6383
International dial-in: (416) 764-8650
Conference ID: 84167910
Webcast: SHWZ Q1 2024 Earnings Call

The conference call will also be broadcast live and available for replay on the investor relations section of the Company’s website at https://ir.schwazze.com.

Toll-free replay number: (888) 390-0541
International replay number: (416) 764-8677
Replay ID: 167910

Advertisement
Stake.com

If you have any difficulty registering or connecting with the conference call, please contact Elevate IR at (720) 330-2829.

About Schwazze

Schwazze (OTCQX: SHWZ) (Cboe CA: SHWZ) is building a premier vertically integrated regional cannabis company with assets in Colorado and New Mexico and will continue to explore taking its operating system to other states where it can develop a differentiated regional leadership position. Schwazze is the parent company of a portfolio of leading cannabis businesses and brands spanning seed to sale.

Schwazze is anchored by a high-performance culture that combines customer-centric thinking and data science to test, measure, and drive decisions and outcomes. The Company’s leadership team has deep expertise in retailing, wholesaling, and building consumer brands at Fortune 500 companies as well as in the cannabis sector.

Medicine Man Technologies, Inc. was Schwazze’s former operating trade name. The corporate entity continues to be named Medicine Man Technologies, Inc. Schwazze derives its name from the pruning technique of a cannabis plant to enhance plant structure and promote healthy growth. To learn more about Schwazze, visit https://schwazze.com/.

Advertisement
Stake.com

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements include financial outlooks; any projections of net sales, earnings, or other financial items; any statements of the strategies, plans and objectives of our management team for future operations; expectations in connection with the Company’s previously announced business plans; any statements regarding future economic conditions or performance; and statements regarding the intent, belief or current expectations of our management team. Such statements may be preceded by the words “may,” “will,” “could,” “would,” “should,” “expect,” “intends,” “plans,” “strategy,” “prospects,” “anticipate,” “believe,” “approximately,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing,” or the negative of these terms or other words of similar meaning in connection with a discussion of future events or future operating or financial performance, although the absence of these words does not necessarily mean that a statement is not forward-looking. We have based our forward-looking statements on management’s current expectations and assumptions about future events and trends affecting our business and industry. Although we do not make forward-looking statements unless we believe we have a reasonable basis for doing so, we cannot guarantee their accuracy. Therefore, forward-looking statements are not guarantees of future events or performance, are based on certain assumptions, and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control and cannot be predicted or quantified. Consequently, actual events and results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) regulatory limitations on our products and services and the uncertainty in the application of federal, state, and local laws to our business, and any changes in such laws; (ii) our ability to manufacture our products and product candidates on a commercial scale on our own or in collaboration with third parties; (iii) our ability to identify, consummate, and integrate anticipated acquisitions; (iv) general industry and economic conditions; (v) our ability to access adequate capital upon terms and conditions that are acceptable to us; (vi) our ability to pay interest and principal on outstanding debt when due; (vii) volatility in credit and market conditions; (viii) the loss of one or more key executives or other key employees; and (ix) other risks and uncertainties related to the cannabis market and our business strategy. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (SEC), including the Company’s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC’s website at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise except as required by law.

Investor Relations Contact
Sean Mansouri, CFA or Aaron D’Souza
Elevate IR
(720) 330-2829
ir@schwazze.com

MEDICINE MAN TECHNOLOGIES, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
For the Periods Ended March 31, 2024 and December 31, 2023
Expressed in U.S. Dollars

 March 31,

Advertisement
Stake.com

December 31, 

2024

2023

 

ASSETS

Advertisement
Stake.com

 

Current Assets

Cash & Cash Equivalents

$

13,151,317

$

Advertisement
Stake.com

19,248,932

Accounts Receivable, net of Allowance for Doubtful Accounts

3,356,032

4,261,159

Inventory

Advertisement
Stake.com

26,382,184

25,787,793

Marketable Securities, net of Unrealized Loss of $347,516 and Loss of $1,816, respectively

108,583

456,099

Advertisement
Stake.com

Prepaid Expenses & Other Current Assets

3,502,310

3,914,064

Total Current Assets

46,500,426

Advertisement
Stake.com

53,668,047

Non-Current Assets

Fixed Assets, net Accumulated Depreciation of $10,061,700 and $8,741,782, respectively

31,326,000

31,113,630

Advertisement
Stake.com

Investments

2,000,000

2,000,000

Investments Held for Sale

Advertisement
Stake.com

202,111

Goodwill

67,492,705

67,499,199

Intangible Assets, net Accumulated Amortization of $36,483,160 and $32,706,765, respectively

Advertisement
Stake.com

162,391,482

166,167,877

Other Non-Current Assets

1,328,187

1,263,837

Advertisement
Stake.com

Operating Lease Right of Use Assets

34,575,832

34,233,142

Deferred Tax Assets, net

992,144

Advertisement
Stake.com

1,996,489

Total Non-Current Assets

300,106,350

304,476,285

Total Assets

Advertisement
Stake.com

$

346,606,776

$

358,144,332

 
Advertisement
Stake.com

LIABILITIES & STOCKHOLDERS’ EQUITY

 

Current Liabilities

Accounts Payable

$

9,443,233

Advertisement
Stake.com

$

13,341,561

Accrued Expenses

8,106,618

7,774,691

Advertisement
Stake.com

Derivative Liabilities

1,319,845

638,020

Lease Liabilities – Current

5,186,316

Advertisement
Stake.com

4,922,724

Current Portion of Long Term Debt

29,579,713

3,547,011

Income Taxes Payable

Advertisement
Stake.com

28,235,039

25,232,782

Total Current Liabilities

81,870,764

55,456,789

Advertisement
Stake.com

Non-Current Liabilities

Long Term Debt, net of Debt Discount & Issuance Costs

130,120,753

153,262,203

Lease Liabilities – Non-Current

Advertisement
Stake.com

30,735,072

30,133,452

Total Non-Current Liabilities

160,855,825

183,395,655

Advertisement
Stake.com

Total Liabilities

$

242,726,589

$

238,852,444

Advertisement
Stake.com

Stockholders’ Equity

Preferred Stock, $0.001 Par Value. 10,000,000 Shares Authorized; 82,185 Shares Issued and

82,185 Outstanding as of March 31, 2024 and 85,534 Shares Issued and 85,534 Outstanding as of

December 31, 2023.

82

Advertisement
Stake.com

86

Common Stock, $0.001 Par Value. 250,000,000 Shares Authorized; 79,168,539 Shares Issued

and 78,248,389 Shares Outstanding as of March 31, 2024 and 74,888,392 Shares Issued

and 73,968,242 Shares Outstanding as of December 31, 2023.

79,169

Advertisement
Stake.com

74,888

Additional Paid-In Capital

202,677,665

202,040,968

Accumulated Deficit

Advertisement
Stake.com

(96,843,602)

(80,790,927)

Common Stock Held in Treasury, at Cost, 920,150 Shares Held as of March 31, 2024 and

920,150 Shares Held as of December 31, 2023.

(2,033,127)

Advertisement
Stake.com

(2,033,127)

Total Stockholders’ Equity

103,880,187

119,291,888

Total Liabilities & Stockholders’ Equity

Advertisement
Stake.com

$

346,606,776

$

358,144,332

MEDICINE MAN TECHNOLOGIES, INC.
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME AND (LOSS)
For the Periods Ended March 31, 2024 and 2023
Expressed in U.S. Dollars

Advertisement
Stake.com

For the Three Months Ended

March 31,

2024

2023

(Unaudited)

Advertisement
Stake.com

(Unaudited)

Operating Revenues

Retail

$

37,633,252

Advertisement
Stake.com

$

35,820,111

Wholesale

3,898,320

4,058,925

Advertisement
Stake.com

Other

69,421

121,900

Total Revenue

41,600,993

Advertisement
Stake.com

40,000,936

Total Cost of Goods & Services

23,667,319

18,152,163

Gross Profit

Advertisement
Stake.com

17,933,674

21,848,773

Operating Expenses

Selling, General and Administrative Expenses

11,835,818

Advertisement
Stake.com

10,100,934

Professional Services

1,671,881

1,187,364

Salaries

Advertisement
Stake.com

6,880,988

4,695,971

Stock Based Compensation

253,916

214,544

Advertisement
Stake.com

Total Operating Expenses

20,642,603

16,198,813

Income from Operations

(2,708,929)

Advertisement
Stake.com

5,649,960

Other Income (Expense)

Interest Expense, net

(8,307,369)

(7,745,854)

Advertisement
Stake.com

Unrealized Gain (Loss) on Derivative Liabilities

(681,825)

8,501,685

Other Loss

10,500

Advertisement
Stake.com

Loss on Investment

(33,382)

Unrealized Gain on Investment

Advertisement
Stake.com

(347,516)

1,816

Total Other Income (Expense)

(9,359,592)

757,647

Advertisement
Stake.com

Pre-Tax Net Income (Loss)

(12,068,521)

6,407,607

Provision for Income Taxes

3,984,154

Advertisement
Stake.com

4,662,178

Net Income (Loss)

$

(16,052,675)

$

Advertisement
Stake.com

1,745,429

Less: Accumulated Preferred Stock Dividends for the Period

(2,155,259)

(2,029,394)

Net Income (Loss) Attributable to Common Stockholders

Advertisement
Stake.com

$

(18,207,934)

$

(283,965)

Earnings (Loss) per Share Attributable to Common Stockholders

Advertisement
Stake.com

Basic Earnings (Loss) per Share

$

(0.24)

$

(0.01)

Advertisement
Stake.com

Diluted Earnings (Loss) per Share

$

(0.24)

$

(0.06)

Advertisement
Stake.com

Weighted Average Number of Shares Outstanding – Basic

76,006,932

55,835,501

Weighted Average Number of Shares Outstanding – Diluted

76,006,932

Advertisement
Stake.com

101,608,278

Comprehensive Income (Loss)

$

(16,052,675)

$

Advertisement
Stake.com

1,745,429

MEDICINE MAN TECHNOLOGIES, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
For the Periods Ended March 31, 2024 and 2023
Expressed in U.S. Dollars

For the Three Months Ended

March 31,

2024

Advertisement
Stake.com

2023

(Unaudited)

(Unaudited)

Cash Flows from Operating Activities:

Net Income (Loss) for the Period

Advertisement
Stake.com

$

(16,052,675)

$

1,745,429

Adjustments to Reconcile Net Income (Loss) to Cash for Operating Activities

Advertisement
Stake.com

Depreciation & Amortization

5,096,314

6,151,395

Non-Cash Interest Expense

1,031,431

Advertisement
Stake.com

991,184

Non-Cash Lease Expense

2,871,226

2,251,459

Deferred Taxes

Advertisement
Stake.com

1,004,345

(637,225)

Loss on Investment

202,111

Advertisement
Stake.com

Change in Derivative Liabilities

681,825

(8,501,685)

Amortization of Debt Issuance Costs

421,512

Advertisement
Stake.com

421,513

Amortization of Debt Discount

2,303,246

1,999,933

(Gain) Loss on Investments, net

Advertisement
Stake.com

347,516

(1,816)

Stock Based Compensation

640,974

214,544

Advertisement
Stake.com

Changes in Operating Assets & Liabilities (net of Acquired Amounts):

Accounts Receivable

905,127

(118,181)

Inventory

Advertisement
Stake.com

(587,900)

(3,023,251)

Prepaid Expenses & Other Current Assets

411,754

(3,036,801)

Advertisement
Stake.com

Other Assets

(64,350)

360,674

Change in Operating Lease Liabilities

(2,348,703)

Advertisement
Stake.com

(1,531,765)

Accounts Payable & Other Liabilities

(3,566,401)

(3,464,671)

Income Taxes Payable

Advertisement
Stake.com

3,002,257

5,299,403

Net Cash Provided by (Used in) Operating Activities

(3,700,390)

(879,861)

Advertisement
Stake.com

Cash Flows from Investing Activities:

Collection of Notes Receivable

10,631

Purchase of Fixed Assets

Advertisement
Stake.com

(1,532,287)

(2,913,394)

Net Cash Provided by (Used in) Investing Activities

(1,532,287)

(2,902,763)

Advertisement
Stake.com

Cash Flows from Financing Activities:

Payment on Notes Payable

(864,938)

Net Cash Provided by (Used in) Financing Activities

Advertisement
Stake.com

(864,938)

Net (Decrease) in Cash & Cash Equivalents

(6,097,615)

(3,782,624)

Advertisement
Stake.com

Cash & Cash Equivalents at Beginning of Period

19,248,932

38,949,253

Cash & Cash Equivalents at End of Period

$

Advertisement
Stake.com

13,151,317

$

35,166,628

Supplemental Disclosure of Cash Flow Information:

Cash Paid for Interest

Advertisement
Stake.com

$

4,515,205

$

6,540,748

MEDICINE MAN TECHNOLOGIES, INC.
ADJUSTED EBITDA RECONCILIATION (NON-GAAP)
For the Periods Ended March 31, 2024 and 2023
Expressed in U.S. Dollars

Advertisement
Stake.com

For the Three Months Ended

March 31,

2024

2023

Net Income (Loss)

Advertisement
Stake.com

$

(16,052,675)

$

1,745,429

Interest Expense, net

Advertisement
Stake.com

8,307,369

7,745,854

Provision for Income Taxes

3,984,154

4,662,178

Advertisement
Stake.com

Other (Income) Expense, net of Interest Expense

1,052,223

(8,503,501)

Depreciation & Amortization

5,618,834

Advertisement
Stake.com

6,612,814

Earnings Before Interest, Taxes, Depreciation and

Amortization (EBITDA) (non-GAAP)

$

2,909,905

Advertisement
Stake.com

$

12,262,774

Non-Cash Stock Compensation

253,916

214,544

Advertisement
Stake.com

Deal Related Expenses

637,761

1,195,802

Capital Raise Related Expenses

20,760

Advertisement
Stake.com

35,068

Severance

484,561

118,436

Retention Program Expenses

Advertisement
Stake.com

807,500

280,632

Pre-Operating & Dark Carry Expenses

1,053,837

391,917

Advertisement
Stake.com

One-Time Legal Settlements

417,653

Other Non-Recurring Items

754,751

Advertisement
Stake.com

25,707

Adjusted EBITDA (non-GAAP)

$

7,340,644

$

Advertisement
Stake.com

14,524,880

Revenue

41,600,993

40,000,936

Adjusted EBITDA Percent

Advertisement
Stake.com

17.6 %

36.3 %

View original content:https://www.prnewswire.co.uk/news-releases/schwazze-announces-first-quarter-2024-financial-results-302146858.html

Continue Reading

SCHWAZZE

Schwazze Sets First Quarter 2024 Conference Call for May 15, 2024 at 5:00 p.m. ET

Published

on

schwazze-sets-first-quarter-2024-conference-call-for-may-15,-2024-at-5:00-pm.-et

DENVER, April 29, 2024 /PRNewswire/ — Medicine Man Technologies, Inc., operating as Schwazze, (OTCQX: SHWZ) (Cboe CA: SHWZ) (“Schwazze” or the “Company”), will host a conference call on Wednesday, May 15, 2024 at 5:00 p.m. Eastern time to discuss its financial and operational results for the first quarter ended March 31, 2024. The Company’s results will be reported in a press release prior to the call.

The Schwazze management team will host the conference call, followed by a question-and-answer period. Interested parties may submit questions to the Company prior to the call by emailing ir@schwazze.com.

Date: Wednesday, May 15, 2024
Time: 5:00 p.m. Eastern time
Toll-free dial-in: (888) 664-6383
International dial-in: (416) 764-8650
Conference ID: 84167910
Webcast: SHWZ Q1 2024 Earnings Call

The conference call will also be broadcast live and available for replay on the investor relations section of the Company’s website at https://ir.schwazze.com.

Toll-free replay number: (888) 390-0541
International replay number: (416) 764-8677
Replay ID: 167910

Advertisement
Stake.com

If you have any difficulty registering or connecting with the conference call, please contact Elevate IR at (720) 330-2829.

About Schwazze

Schwazze (OTCQX: SHWZ) (Cboe CA: SHWZ) is building a premier vertically integrated regional cannabis company with assets in Colorado and New Mexico and will continue to take its operating system to other states where it can develop a differentiated regional leadership position. Schwazze is the parent company of a portfolio of leading cannabis businesses and brands spanning seed to sale.

Schwazze is anchored by a high-performance culture that combines customer-centric thinking and data science to test, measure, and drive decisions and outcomes. The Company’s leadership team has deep expertise in retailing, wholesaling, and building consumer brands at Fortune 500 companies as well as in the cannabis sector.

Medicine Man Technologies, Inc. was Schwazze’s former operating trade name. The corporate entity continues to be named Medicine Man Technologies, Inc. Schwazze derives its name from the pruning technique of a cannabis plant to enhance plant structure and promote healthy growth. To learn more about Schwazze, visit http://www.schwazze.com/.

Investor Relations Contact

Advertisement
Stake.com

Sean Mansouri, CFA or Aaron D’Souza
Elevate IR
(720) 330-2829
ir@schwazze.com

View original content:https://www.prnewswire.co.uk/news-releases/schwazze-sets-first-quarter-2024-conference-call-for-may-15-2024-at-500-pm-et-302130423.html

Continue Reading

SCHWAZZE

Schwazze Announces Fourth Quarter and Full Year 2023 Financial Results

Published

on

schwazze-announces-fourth-quarter-and-full-year-2023-financial-results

 FY 2023 Revenue of $172.4 Million; Income from Operations of $3.3 Million; Adjusted EBITDA of $53.4 Million or 31% of Revenue

 Generated $12.2 Million of Operating Cash Flow in FY 2023

DENVER, March 27, 2024 /PRNewswire/ — Medicine Man Technologies, Inc., operating as Schwazze, (OTCQX: SHWZ) (Cboe: SHWZ) (“Schwazze” or the “Company”), today announced financial and operational results for the fourth quarter and full year ended December 31, 2023.

“This past year, the Schwazze team delivered solid top-line growth in two highly competitive markets with 31% adjusted EBITDA margins and improved operating cash flow,” said Forrest Hoffmaster, Interim CEO of Schwazze. “We continued to sharpen our retail strategy while expanding our store footprint by more than 50% to 63 dispensaries across our two markets. Although the Colorado and New Mexico markets were pressured in 2023, we have built a solid foundation with best-in-class service for our patients and customers. Internally, we are also relentlessly focused on maximizing the operating efficiencies of our manufacturing and cultivation facilities to drive higher yields, improved flower quality, and greater output.”

“With strong demand and over 680 recreational retail stores at year-end, the competitive landscape in Colorado is fierce, underscoring the importance of our investments in and attention to elevating the customer experience. We significantly outpaced the market in Q4 on a sequential and year-over-year basis and expect to bolster our growth through improvements in customer acquisition, retention, and loyalty, as well as in the overall retail experience. Additionally, we are beginning to see wholesale pricing stabilize, which we anticipate will continue based on plant counts and ongoing retail pricing pressure.”

Advertisement
Stake.com

“In New Mexico, the proliferation of new licenses has led to increased competition and aggressive pricing strategies from certain players. Cannabis sales in the state were up 18% across a store base that was over 50% higher year-over-year in Q4, leading to lower average revenue per store. While we are beginning to see a slow-down in net new store openings, we anticipate a challenging market ahead. We remain focused on cost optimization and asset utilization while implementing a balanced pricing and promotional strategy to drive traffic into our stores, where we believe we excel in delivering an elevated retail experience. We are committed to fulfilling our promise of being the retailer of choice in New Mexico.”

“Looking ahead, we are optimistic about the regulatory momentum in the industry at large. In the meantime, we will continue to elevate the customer experience, improve our loyalty program, increase our cost efficiencies, and enhance our retail assets. Our team has a demonstrated track record of executing in competitive markets like Colorado and New Mexico where we remain one of the largest operators. We look forward to driving growth and profitability across each of our markets in 2024.”

Fourth Quarter 2023 Financial Summary

$ in Thousands USD

Q4 2023

Advertisement
Stake.com

Q3 2023

Q4 2022

Total Revenue

$43,325

$46,747

Advertisement
Stake.com

$40,147

Gross Profit

$7,034

$21,438

$21,719

Advertisement
Stake.com

Adjusted Gross Profit[1]

$20,180

$21,438

$21,719

Operating Expenses

Advertisement
Stake.com

$23,276

$12,514

$24,224

Income (Loss) from Operations

$(16,242)

Advertisement
Stake.com

$8,924

$(2,505)

Adjusted EBITDA[2]

$10,953

$14,119

Advertisement
Stake.com

$13,285

Operating Cash Flow

$3,452

$6,946

$6,260

Advertisement
Stake.com

Full Year 2023 Financial Summary

$ in Thousands USD

FY 2023

FY 2022

Total Revenue

Advertisement
Stake.com

$172,448

$159,379

Gross Profit

$76,024

$80,289

Advertisement
Stake.com

Adjusted Gross Profit1

$89,170

$86,830

Operating Expenses

$72,735

Advertisement
Stake.com

$67,434

Income from Operations

$3,289

$12,855

Adjusted EBITDA2

Advertisement
Stake.com

$53,412

$52,010

Operating Cash Flow

$12,201

$6,694

Advertisement
Stake.com

___________________________

1  Adjusted Gross Profit is a non-GAAP measure as defined by the SEC and represents gross profit excluding non-cash inventory adjustments. The Company uses Adjusted Gross Profit as it believes it better explains the results of its core business. See “ADJUSTED GROSS PROFIT RECONCILIATION (NON-GAAP)” section herein for an explanation and reconciliations of non-GAAP measure used throughout this release.

2  Adjusted EBITDA is a non-GAAP measure as defined by the SEC, and represents earnings before interest, taxes, depreciation, and amortization, adjusted for other income, non-cash share-based compensation, one-time transaction related expenses, or other non-operating costs. The Company uses Adjusted EBITDA as it believes it better explains the results of its core business. See “ADJUSTED EBITDA RECONCILIATION (NON-GAAP)” section herein for an explanation and reconciliations of non-GAAP measure used throughout this release.

Full Year 2023 Operational Highlights

  • Expanded the Company’s retail footprint by more than 50% in New Mexico and Colorado to 63 dispensaries.
  • Completed the acquisition of Everest Apothecary, adding 14 dispensaries, one cultivation facility, and one manufacturing plant to the Company’s New Mexico operations.
  • Acquired Standing Akimbo, the largest medical cannabis dispensary in Colorado, and opened the Company’s first medical dispensary in Colorado Springs under the Standing Akimbo banner.
  • Acquired two Colorado retail dispensaries in Fort Collins and Garden City from Smokey’s.
  • Unveiled an enhanced, custom ecommerce platform in New Mexico under the R. Greenleaf banner.
  • Increased wholesale penetration in Colorado and New Mexico by over 3x year-over-year to more than 27% total door penetration in both states.
  • Grew Lowell Farms pre-roll sales by over 250% in Colorado where it is now the #1 pre-roll in the state. In addition, Lowell is in six of the largest Colorado accounts and will be available for wholesale in New Mexico starting April 1st, 2024.
  • Grew sales with Wana, our fan-favorite gummies brand, by 48% in New Mexico where it is now in 130 doors with eight of the top ten accounts in the state.

Fourth Quarter 2023 Financial Results

Total revenue in the fourth quarter of 2023 increased 8% to $43.3 million compared to $40.1 million for the same quarter last year. The increase was primarily due to growth from new stores compared to the prior year period and increased wholesale revenue, partially offset by pricing pressure from the proliferation of new licenses in New Mexico.

Advertisement
Stake.com

Gross profit for the fourth quarter of 2023 was $7.0 million or 16.2% of total revenue, compared to $21.7 million or 54.1% of total revenue for the same quarter last year. The decrease in gross margin was primarily driven by one-time, non-cash inventory adjustments of approximately $13.1 million comprised of $3.1 million of product consolidation, obsolescence, and shrinkage expenses, $4.3 million of net realizable value adjustments, and $5.8 million of fair value adjustments on acquired inventory in New Mexico in 2023. Adjusted gross profit, which excludes non-cash inventory adjustments, for the fourth quarter of 2023 was $20.2 million or 46.6% of revenue.

Operating expenses for the fourth quarter of 2023 were $23.3 million compared to $24.2 million for the same quarter last year. The decrease was primarily due to a lower impairment charge in the fourth quarter of 2023. This was partially offset by an increase in four-wall SG&A expenses associated with the 22 additional stores in Colorado and New Mexico that are still ramping, as well as greater salaries and stock-based compensation.

Loss from operations for the fourth quarter of 2023 was $16.2 million compared to $2.5 million in the same quarter last year. The decrease was driven by the aforementioned lower gross profit, primarily related to the non-cash inventory adjustment. Net loss was $33.9 million for the fourth quarter of 2023 compared to $27.3 million for the same quarter last year.

Adjusted EBITDA for the fourth quarter of 2023 was $11.0 million or 25.3% of revenue, compared to $13.3 million or 33.1% of revenue for the same quarter last year. The decrease in Adjusted EBITDA margin was primarily driven by higher operating expenses associated with the 22 additional stores that are still ramping.

As of December 31, 2023, cash and cash equivalents were $19.2 million compared to $38.9 million on December 31, 2022. Total debt as of December 31, 2023, was $156.8 million compared to $127.8 million on December 31, 2022.

Advertisement
Stake.com

Conference Call

The Company will conduct a conference call today, March 27, 2024, at 5:00 p.m. Eastern time to discuss its results for the fourth quarter and full year ended December 31, 2023.

Schwazze management will host the conference call, followed by a question-and-answer period. Interested parties may submit questions to the Company prior to the call by emailing ir@schwazze.com.

Date: Wednesday, March 27, 2024
Time: 5:00 p.m. Eastern time
Toll-free dial-in: (888) 664-6383
International dial-in: (416) 764-8650
Conference ID: 38840334
Webcast: SHWZ Q4 & FY 2023 Earnings Call

The conference call will also be broadcast live and available for replay on the investor relations section of the Company’s website at https://ir.schwazze.com.

Advertisement
Stake.com

Toll-free replay number: (888) 390-0541
International replay number: (416) 764-8677
Replay ID: 840334

If you have any difficulty registering or connecting with the conference call, please contact Elevate IR at (720) 330-2829.

About Schwazze

Schwazze (OTCQX: SHWZ) (Cboe: SHWZ) is building a premier vertically integrated regional cannabis company with assets in Colorado and New Mexico and will continue to explore taking its operating system to other states where it can develop a differentiated regional leadership position. Schwazze is the parent company of a portfolio of leading cannabis businesses and brands spanning seed to sale.

Schwazze is anchored by a high-performance culture that combines customer-centric thinking and data science to test, measure, and drive decisions and outcomes. The Company’s leadership team has deep expertise in retailing, wholesaling, and building consumer brands at Fortune 500 companies as well as in the cannabis sector.

Medicine Man Technologies, Inc. was Schwazze’s former operating trade name. The corporate entity continues to be named Medicine Man Technologies, Inc. Schwazze derives its name from the pruning technique of a cannabis plant to enhance plant structure and promote healthy growth. To learn more about Schwazze, visit https://schwazze.com/.

Advertisement
Stake.com
Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements include financial outlooks; any projections of net sales, earnings, or other financial items; any statements of the strategies, plans and objectives of our management team for future operations; expectations in connection with the Company’s previously announced business plans; any statements regarding future economic conditions or performance; and statements regarding the intent, belief or current expectations of our management team. Such statements may be preceded by the words “may,” “will,” “could,” “would,” “should,” “expect,” “intends,” “plans,” “strategy,” “prospects,” “anticipate,” “believe,” “approximately,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing,” or the negative of these terms or other words of similar meaning in connection with a discussion of future events or future operating or financial performance, although the absence of these words does not necessarily mean that a statement is not forward-looking. We have based our forward-looking statements on management’s current expectations and assumptions about future events and trends affecting our business and industry. Although we do not make forward-looking statements unless we believe we have a reasonable basis for doing so, we cannot guarantee their accuracy. Therefore, forward-looking statements are not guarantees of future events or performance, are based on certain assumptions, and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control and cannot be predicted or quantified. Consequently, actual events and results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) regulatory limitations on our products and services and the uncertainty in the application of federal, state, and local laws to our business, and any changes in such laws; (ii) our ability to manufacture our products and product candidates on a commercial scale on our own or in collaboration with third parties; (iii) our ability to identify, consummate, and integrate anticipated acquisitions; (iv) general industry and economic conditions; (v) our ability to access adequate capital upon terms and conditions that are acceptable to us; (vi) our ability to pay interest and principal on outstanding debt when due; (vii) volatility in credit and market conditions; (viii) the loss of one or more key executives or other key employees; and (ix) other risks and uncertainties related to the cannabis market and our business strategy. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (SEC), including the Company’s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC’s website at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise except as required by law.

Investor Relations Contact
Sean Mansouri, CFA or Aaron D’Souza
Elevate IR
(720) 330-2829
ir@schwazze.com

MEDICINE MAN TECHNOLOGIES, INC.
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME AND (LOSS)
For the Periods Ended December 31, 2023 and 2022
Expressed in U.S. Dollars

For the Three Months Ended

For the Twelve Months Ended

Advertisement
Stake.com

December 31,

December 31,

2023

2022

2023

Advertisement
Stake.com

2022

(Unaudited)

(Unaudited)

(Audited)

(Audited)

Advertisement
Stake.com

Operating Revenues

Retail

$

39,592,779

$

Advertisement
Stake.com

36,868,429

$

155,463,816

$

141,254,893

Advertisement
Stake.com

Wholesale

3,730,749

3,158,670

16,765,425

17,819,938

Advertisement
Stake.com

Other

1,287

120,188

218,545

304,388

Advertisement
Stake.com

Total Revenue

43,324,815

40,147,287

172,447,786

159,379,219

Advertisement
Stake.com

Total Cost of Goods & Services

36,291,059

18,428,528

96,424,150

79,090,461

Advertisement
Stake.com

Gross Profit

7,033,756

21,718,759

76,023,636

80,288,758

Advertisement
Stake.com

Operating Expenses

Selling, General and Administrative Expenses

10,848,029

8,922,627

39,916,518

Advertisement
Stake.com

29,036,962

Professional Services

1,115,457

1,112,975

3,558,501

Advertisement
Stake.com

6,722,554

Loss on Impairment

1,810,890

8,011,405

1,801,740

Advertisement
Stake.com

8,011,405

Salaries

6,561,800

5,292,996

23,883,354

Advertisement
Stake.com

20,990,290

Stock Based Compensation

2,952,669

883,890

3,574,831

Advertisement
Stake.com

2,672,713

Total Operating Expenses

23,288,845

24,223,893

72,734,944

Advertisement
Stake.com

67,433,924

Income from Operations

(16,255,089)

(2,505,134)

3,288,692

Advertisement
Stake.com

12,854,834

Other Income (Expense)

Interest Expense, net

(8,112,391)

(6,827,557)

Advertisement
Stake.com

(32,069,082)

(30,139,645)

Unrealized Gain (Loss) on Derivative Liabilities

1,384,228

(9,690,200)

Advertisement
Stake.com

15,870,233

18,414,760

Other Loss

68,400

3,736

Advertisement
Stake.com

68,400

24,136

Loss on Business Disposition

(1,968,807)

(4,684,366)

Advertisement
Stake.com

(1,968,807)

(4,684,366)

Unrealized Gain (Loss) on Investments

3,083

Advertisement
Stake.com

1,816

(39,270)

Total Other Income (Expense)

(8,628,570)

(21,195,304)

Advertisement
Stake.com

(18,097,441)

(16,424,385)

Pre-Tax Net Income (Loss)

(24,883,659)

(23,700,438)

Advertisement
Stake.com

(14,808,749)

(3,569,551)

Provision for Income Taxes

4,494,049

3,638,695

Advertisement
Stake.com

19,740,595

14,898,064

Net Income (Loss)

$

(29,377,708)

Advertisement
Stake.com

$

(27,339,133)

$

(34,549,344)

$

Advertisement
Stake.com

(18,467,615)

Less: Accumulated Preferred Stock Dividends for the Period

(1,541,341)

(2,508,677)

(8,154,993)

Advertisement
Stake.com

(7,802,809)

Net Income (Loss) Attributable to Common Stockholders

$

(30,919,049)

$

Advertisement
Stake.com

(29,847,810)

$

(42,704,337)

$

(26,270,424)

Advertisement
Stake.com

Earnings (Loss) per Share Attributable to Common Stockholders

Basic Earnings (Loss) per Share

$

(0.43)

$

Advertisement
Stake.com

(0.57)

$

(0.66)

$

(0.49)

Advertisement
Stake.com

Diluted Earnings (Loss) per Share

$

(0.43)

$

(0.57)

Advertisement
Stake.com

$

(0.66)

$

(0.49)

Weighted Average Number of Shares Outstanding – Basic

Advertisement
Stake.com

71,680,200

53,637,003

64,535,245

53,637,003

Weighted Average Number of Shares Outstanding – Diluted

Advertisement
Stake.com

71,680,200

53,637,003

64,535,245

53,637,003

Comprehensive Income (Loss)

Advertisement
Stake.com

$

(29,377,708)

$

(27,339,133)

$

Advertisement
Stake.com

(34,549,344)

$

(18,467,615)

MEDICINE MAN TECHNOLOGIES, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
For the Periods Ended December 31, 2023 and 2022
Expressed in U.S. Dollars

For the Twelve Months Ended

Advertisement
Stake.com

December 31,

2023

2022

(Audited)

(Audited)

Advertisement
Stake.com

Cash Flows from Operating Activities:

Net Income (Loss) for the Period

$

(34,549,344)

$

Advertisement
Stake.com

(18,467,615)

Adjustments to Reconcile Net Income (Loss) to Cash for Operating Activities

Depreciation & Amortization

20,933,541

10,660,172

Advertisement
Stake.com

Non-Cash Interest Expense

4,024,604

4,118,391

Impairment of Goodwill

1,801,740

Advertisement
Stake.com

8,011,405

Non-Cash Lease Expense

7,648,531

3,910,679

Deferred Taxes

Advertisement
Stake.com

(2,090,967)

502,070

Loss on Disposition of Business Units

1,968,807

4,684,369

Advertisement
Stake.com

Change in Derivative Liabilities

(15,870,233)

(18,414,760)

Amortization of Debt Issuance Costs

1,686,049

Advertisement
Stake.com

1,686,048

Amortization of Debt Discount

8,523,493

7,484,613

(Gain) Loss on Investments, net

Advertisement
Stake.com

(1,816)

39,270

Stock Based Compensation

3,590,473

812,073

Advertisement
Stake.com

Changes in Operating Assets & Liabilities (net of Acquired Amounts):

Accounts Receivable

927,259

(105,185)

Inventory

Advertisement
Stake.com

4,571,069

789,399

Prepaid Expenses & Other Current Assets

1,579,349

(2,770,179)

Advertisement
Stake.com

Other Assets

263,419

(248,682)

Change in Operating Lease Liabilities

(7,498,128)

Advertisement
Stake.com

(13,113,041)

Accounts Payable & Other Liabilities

(3,241,850)

11,845,245

Income Taxes Payable

Advertisement
Stake.com

17,934,967

5,270,074

Net Cash Provided by (Used in) Operating Activities

12,200,963

6,694,346

Advertisement
Stake.com

Cash Flows from Investing Activities:

Collection of Notes Receivable

11,944

Cash Consideration for Acquisition of Business, net of Cash Acquired

Advertisement
Stake.com

(15,834,378)

(58,981,226)

Purchase of Fixed Assets

(7,865,654)

(14,007,892)

Advertisement
Stake.com

Purchase of Intangible Assets

(2,750,000)

Investment in Private Entity

Advertisement
Stake.com

(2,000,000)

Net Cash Provided by (Used in) Investing Activities

(26,438,088)

(74,989,118)

Cash Flows from Financing Activities:

Advertisement
Stake.com

Payment on Notes Payable

(5,354,218)

(134,498)

Proceeds from Issuance of Common Stock

Advertisement
Stake.com

978,308

Payment for Statutory Withholdings on RSU

(108,978)

Net Cash Provided by (Used in) Financing Activities

Advertisement
Stake.com

(5,463,196)

843,810

Net (Decrease) in Cash & Cash Equivalents

(19,700,321)

(67,450,962)

Advertisement
Stake.com

Cash & Cash Equivalents at Beginning of Period

38,949,253

106,400,216

Cash & Cash Equivalents at End of Period

$

Advertisement
Stake.com

19,248,932

$

38,949,253

Supplemental Disclosure of Cash Flow Information:

Cash Paid for Interest

Advertisement
Stake.com

$

17,896,954

$

15,243,990

Cash Paid for Income Taxes

Advertisement
Stake.com

5,000,000

12,340,000

MEDICINE MAN TECHNOLOGIES, INC.
ADJUSTED EBITDA RECONCILIATION (NON-GAAP)
For the Periods Ended December 31, 2023 and 2022
Expressed in U.S. Dollars

For the Three Months Ended

For the Twelve Months Ended

Advertisement
Stake.com

December 31,

December 31,

2023

2022

2023

Advertisement
Stake.com

2022

Net Income (Loss)

$

(29,364,680)

$

Advertisement
Stake.com

(27,339,133)

$

(34,549,344)

$

(18,467,615)

Advertisement
Stake.com

Interest Expense, net

8,112,391

6,827,557

32,069,082

30,139,645

Advertisement
Stake.com

Provision for Income Taxes

4,494,049

3,638,695

19,740,595

14,898,064

Advertisement
Stake.com

Other (Income) Expense, net of Interest Expense

516,180

14,367,747

(13,971,641)

(13,715,260)

Advertisement
Stake.com

Depreciation & Amortization

3,162,425

3,701,128

18,970,960

12,524,677

Advertisement
Stake.com

Earnings Before Interest, Taxes, Depreciation and

Amortization (EBITDA) (non-GAAP)

$

(13,079,635)

$

Advertisement
Stake.com

1,195,994

$

22,259,652

$

25,379,511

Advertisement
Stake.com

Non-Cash Stock Compensation

1,597,157

883,890

2,219,319

2,672,713

Advertisement
Stake.com

Deal Related Expenses

2,196,733

1,914,820

5,528,048

6,822,111

Advertisement
Stake.com

Capital Raise Related Expenses

1,779

(257,271)

38,559

533,958

Advertisement
Stake.com

Inventory Adjustment to Fair Market Value for

Purchase Accounting

5,792,488

5,792,488

Advertisement
Stake.com

6,541,651

One-Time Inventory Impairment

7,353,972

7,353,972

Advertisement
Stake.com

One-Time Goodwill Impairment

1,801,740

8,011,405

1,801,740

Advertisement
Stake.com

8,011,405

Severance

111,752

263,374

537,584

Advertisement
Stake.com

334,910

Retention Program Expenses

505,655

Advertisement
Stake.com

Employee Relocation Expenses

5,065

(3,750)

70,107

Advertisement
Stake.com

15,360

Pre-Operating & Dark Carry Expenses

2,663,824

1,027,738

2,663,824

Advertisement
Stake.com

1,027,738

One-Time Legal Settlements

1,204,058

440,000

1,204,058

Advertisement
Stake.com

440,000

Other Non-Recurring Items

1,304,501

(191,674)

3,436,773

Advertisement
Stake.com

230,858

Adjusted EBITDA (non-GAAP)

$

10,953,434

$

Advertisement
Stake.com

13,284,526

$

53,411,779

$

52,010,215

Advertisement
Stake.com

Revenue

43,324,815

40,147,287

172,447,786

159,379,219

Advertisement
Stake.com

Adjusted EBITDA Percent

25.3 %

33.1 %

31.0 %

32.6 %

Advertisement
Stake.com

View original content:https://www.prnewswire.co.uk/news-releases/schwazze-announces-fourth-quarter-and-full-year-2023-financial-results-302101678.html

Continue Reading
Advertisement
Stake.com

Latest news

Trending on Grassnews

GrassNews.net: Your premier portal for the latest developments in the cannabis industry. We provide timely news, insightful analysis, and in-depth features on everything from legislation changes and business trends, to scientific research and lifestyle topics. Stay informed and navigate the rapidly evolving cannabis landscape with GrassNews.net..

Contact us: sales@hipther.agency

Editorial / PR Submissions

Copyright © 2007 - 2024 Hipther Agency. Registered in Romania under Proshirt SRL, Company number: 2134306, EU VAT ID: RO21343605. Office address: Blvd. 1 Decembrie 1918 nr.5, Targu Mures, Romania